LCC-CARIS-01: Molecular profiling in gynaecological cancer.

  • Research type

    Research Study

  • Full title

    LCC-CARIS-01: A pilot feasibility study to assess the use of molecular profiling to determine choice of treatment for patients with gynaecological cancer.

  • IRAS ID

    188747

  • Contact name

    Geoff Hall

  • Contact email

    geoff.hall2@nhs.net

  • Sponsor organisation

    University of Leeds

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    In the UK, women with gynaecological cancers (which include cancers of the ovaries, fallopian tubes, cervix, uterus and peritoneum) are generally treated with chemotherapy and/or hormonal treatment. In some instances these cancers may come back despite initial treatment, in which case they are described as recurrent. At present, there is no specific tool to help doctors caring for patients with recurrent cancers of the ovaries, fallopian tubes or peritoneum, or those with a number of other gynaecological cancers, to choose the best treatment for their patient. They must therefore instead choose treatments based on those seen to be most successful in other patients with similar cancers, often when evidence for which is most successful is very limited.

    A fundamental goal of treating cancer patients is to recommend the most effective treatment suggested by current scientific evidence. Recent advances in our understanding of cancer have resulted in the development of a tool – Caris Molecular Intelligence (CMI) - capable of analysing biopsies or surgically removed tumours to identify specific ‘tumour biomarkers’ present in a patient’s cancer. This pilot feasibility study will take place in Leeds Cancer Centre, which is part of Leeds Teaching Hospitals NHS Trust (with patients recruited from a total of six sites) and will aim to see whether the CMI tool can be successfully used by doctors working in the NHS to identify biomarkers present in a patient’s tumour, and whether knowledge of these biomarkers changes the treatment that a doctor would choose to provide for a patient with cancer.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    15/YH/0493

  • Date of REC Opinion

    15 Dec 2015

  • REC opinion

    Further Information Favourable Opinion